Ashvattha Therapeutics to Present Late-Breaking Phase 2 DME and nAMD Data at 25th EURETINA Congress

Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME and nAMD

Subcutaneous at-home administration represents a potential paradigm shift from frequent in-office intravitreal injections

Chief Medical Officer also to present at the Ophthalmology Futures Forums: Retina Forum 2025

REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in regions of inflammation selectively targeting and reprogramming activated cells in the retina, today announced it will present at the 25^th European Society of Retina Specialists (EURETINA) Congress, September 4 –7, 2025 in Paris, France.

The presentation will feature topline 40-week Phase 2 study data of migaldendranib (MGB), the company’s investigational first-in-class subcutaneous nanomedicine being developed for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). MGB is designed to cross the blood-retinal barrier in regions of inflammation and selectively normalize VEGF expression in activated retinal cells.

Presentation details:

Ophthalmology Futures Forums: Retina Forum 2025:

• Panel Title: Panel 4: The Future of Tyrosine Kinase Inhibitors & Other Adjunctive Agents for AMD: Exits or Bust?
• Date/Time: Wednesday, September 3, 2025; 11:50 – 12:20 CEST
• Panelist: Susan Schneider, MD, Acting Chief Medical Officer of Ashvattha Therapeutics

• Presentation Title: Company Presentations 1
• Date/Time: Wednesday, September 3, 2025; 13:50 – 15:20 CEST
• Presenter: Susan Schneider, MD, Acting Chief Medical Officer of Ashvattha Therapeutics

EURETINA Congress:

• Presentation Title: Subcutaneous Migaldendranib for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration: First Time 40-week Results from a Phase 2 Trial
• Presentation Date/Time: Friday, September 5, 2025; 15:27 – 15:33 CEST
• Session: Euretina Session 7 – First Time Clinical Trials & Late Breaking Session
• Presenter: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research at Sierra Eye Associates

About Migaldendranib
Migaldendranib (MGB) is a novel first-in-class nanomedicine in clinical development for the treatment of DME and nAMD. Administered subcutaneously, MGB has a differentiated mechanism of action that crosses the blood-retinal barrier in regions of inflammation and selectively normalizes VEGF expression in activated macrophages, microglia, and retinal pigment epithelial cells in the retina. Phase 2 clinical results demonstrate that subcutaneous MGB is safe and well-tolerated across multiple doses, with the potential for convenient once-monthly at-home administration that could significantly reduce intravitreal injection burden for patients, including those with bilateral disease.

About Ashvattha Therapeutics 
Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells only in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care in ophthalmology. Ashvattha Therapeutics was founded by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland and incubated by Natural Capital. For more information, visit: www.avttx.com

Media
ICR Healthcare
AshvatthaPR@icrhealthcare.com

Investor Relations
Aman Patel, CFA & Adanna G. Alexander, PhD
AshvatthaIR@icrhealthcare.com